
Martin S Maron MD
Adult Congenital Heart Disease
Assistant Professor of Medicine
Join to View Full Profile
41 Mall RdBurlington, MA 01805
Phone+1 781-744-8000
Fax+1 617-636-6204
Dr. Maron is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Martin Maron, MD, serves as the Director of the Hypertrophic Cardiomyopathy Center and the Co-Director of the Cardiac CT and MRI program at Tufts Medical Center and Associate Professor at Tufts University School of Medicine. His specialties include cardiac imagining, hypertrophic cardiomyopathy, and cardiac magnetic resonance imaging. He was the Hypertrophic Cardiomyopathy Association’s 2011 Clinician of the Year, and currently serves on the association’s Board of Directors. He is board certified in Cardiovascular Disease and Internal Medicine.
Education & Training
Tufts Medical CenterFellowship, Cardiovascular Disease, 2002 - 2005
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2001
Tulane University School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2027
NH State Medical License 2024 - 2026
NJ State Medical License 2013 - 2023
FL State Medical License 2019 - 2021
American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Clinical Trials
- Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Start of enrollment: 2007 Nov 01
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
- Extended ECG Monitoring in HCM Patients Start of enrollment: 2020 Jan 14
Publications & Presentations
PubMed
- Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.Albree Tower-Rader, Ahmad Masri, Michael E Nassif, Theodore P Abraham, Roberto Barriales-Villa
European Heart Journal. 2026-06-23 - Electrocardiographic features of left bundle branch block after septal myectomy for obstructive hypertrophic cardiomyopathy.Benjamin L Freedman, Divya Velury, Libin Wang, Austin Burrows, Charles Miller
Heart Rhythm. 2026-06-01 - 3 citationsConcomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.Ahmad Masri, Martin S Maron, Theodore P Abraham, Michael E Nassif, Roberto Barriales-Villa
JACC. Heart Failure. 2026-02-01
Journal Articles
- Mini-Focus Issue: Hypertrophic Cardiomyopathy State-of-the-Art Review Clinical Spectrum and Management of Heart Failure in Hypertrophic CardiomyopathyMartin S Maron, Barry J Maron, James E Udelson, Ethan J Rowin, ScienceDirect
Lectures
- HCM and its Many Variations: When to Suspect and How to Diagnose?2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Other
- Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathyMaron MS, Elliott PM
http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-hypertrophic-ca
UpToDate, Wolters Kluwer Health - 2012-12-13 - Overview of hypertrophic cardiomyopathy management including treatment of special problemsMaron MS
http://www.uptodate.com/contents/overview-of-hypertrophic-cardiomyopathy-management-including-treatm
UpToDate, Wolters Kluwer Health - 2012-12-06
Press Mentions
In Memoriam: Eugene Braunwald, MD, MACCApril 23rd, 2026
FDA Approves New Drug for Genetic Heart DiseaseDecember 19th, 2025
Aficamten Effective, Safe in Patients with Mild Obstructive HCM SymptomsMay 29th, 2025
Grant Support
- Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMRBETH ISRAEL DEACONESS MEDICAL CENTER2025–2030
- Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCMBETH ISRAEL DEACONESS MEDICAL CENTER2021–2025
- Clinical And Therapeutic Implications Of Fibrosis In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









